Farallon Capital Management Adds $52M in Immunovant, Inc. ($IMVT)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Farallon Capital Management increased its position in Immunovant, Inc. ($IMVT) by 12783.33% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,546,000 shares of Immunovant, Inc. after buying 1,534,000 shares during the quarter. Farallon Capital Management's holdings in Immunovant, Inc. were worth $51.98 million as of its most recent filing.
Immunovant, Inc. Stock Down 18.4%
Shares of Immunovant, Inc. ($IMVT) traded around $33.62 on Saturday, down 18.4% for the day.
Immunovant, Inc. Earnings
Analysts Set New Price Targets
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Get Immunovant, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMVT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.